Clinical Edge Journal Scan

Residual TNBC: Platinum therapy does not improve outcomes


 

Key clinical point: Platinum agents do not improve outcomes in patients with basal subtype triple-negative breast cancer ( TNBC) and residual invasive disease post-neoadjuvant chemotherapy (NAC) and are associated with higher toxicity rate vs. capecitabine.

Major finding: The invasive disease-free survival was not significantly different between platinum and capecitabine groups (hazard ratio, 1.06; 95% confidence interval, 0.62-1.81) after a median follow-up of 20 months. Grade 3 and 4 toxicities were more frequent in the platinum vs. capecitabine group (26% vs. 15%).

Study details: A phase 3, randomized controlled EA1131 trial involving 415 patients with stage II-III TNBC post-NAC, randomly assigned to receive platinum-based chemotherapy or capecitabine.

Disclosures: This study was supported by the National Cancer Institute of the National Institutes of Health. The authors received consulting/advisory fees, research funding, honoraria, travel/accommodation/expenses, and reported stock and other ownership interests in various companies. Some authors also reported patents, royalties, and other intellectual property.

Source: Mayer IA et al. J Clin Oncol. 2021 Jun 6. doi: 10.1200/JCO.21.00976.

Recommended Reading

Genomic signature predicts safety of omitting RT in early breast cancer
Breast Cancer ICYMI
CONCERT: Better QoL but not survival with cabazitaxel in metastatic HER2– breast cancer
Breast Cancer ICYMI
Pilot study: Hybrid laser found effective for treating genitourinary syndrome of menopause
Breast Cancer ICYMI
How to choose the right vaginal moisturizer or lubricant for your patient
Breast Cancer ICYMI
Promising HER2+/HR– breast cancer survival with de-escalated therapy
Breast Cancer ICYMI
Freezing breast cancer to death avoids surgery: Why not further along?
Breast Cancer ICYMI
Key strategies for managing breast cancer brain metastases
Breast Cancer ICYMI
DCIS: Biosignature helps guide postlumpectomy decisions
Breast Cancer ICYMI
Clinical Edge Journal Scan Commentary: Breast Cancer July 2021
Breast Cancer ICYMI
Adjuvant olaparib yields survival benefit in HER2-negative BRCA1/2 breast cancer
Breast Cancer ICYMI